Physician profile
Lisa Baker
NPI 1639176571
$2,344.85
in general payments reported to CMS, 2019-2025
29 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $260 · 2021: $67.97 · 2022: $234 · 2023: $410 · 2024: $165 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $486.78 | 2019-2025 | Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $266.33 | 2019-2023 | Trintellix |
| Abbvie INC. | $229.33 | 2019-2023 | Qulipta, Liletta |
| Merck Sharp & Dohme LLC | $183.45 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Leo Pharma INC. | $138.91 | 2019-2020 | |
| Astellas Pharma US INC | $137.99 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $129.53 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $96.87 | 2023-2025 | Myfembree, Gemtesa |
| Allergan, INC. | $82.13 | 2019-2020 | |
| Organon LLC | $81.39 | 2022-2023 | Nexplanon |
| Exact Sciences Corporation | $46.44 | 2023 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $44.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.49 | 2024 | |
| Glaxosmithkline, LLC. | $39.40 | 2019-2022 | |
| Millicent US INC | $38.13 | 2024-2025 | Femlyv, Intrarosa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.85 | 2019 | |
| Lilly USA, LLC | $35.56 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $29.37 | 2019-2024 | Breztri |
| Abbott Laboratories | $26.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.99 | 2020 | |
| Amarin Pharma, INC. | $23.55 | 2019 | |
| Exeltis, USA INC. | $20.73 | 2025 | Slynd |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.39 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.69 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.76 | 2024 | Xarelto |
| Coopersurgical, INC. | $13.91 | 2020 | |
| Currax Pharmaceuticals LLC | $12.80 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.